MLPH Peptide Hair Growth Mechanism: How EPOR-IGF-1 Signaling May Switch Dermal Papilla Cells Back Into Anagen Mode

The most important thing about the new MLPH peptide study is not just that it made hair shafts grow longer in human follicle culture. It is how it appears to do it: by turning on an erythropoietin-receptor signal inside dermal papilla cells, then pushing those cells to release more IGF-1, one of the follicle’s most important growth-supporting messages.

That matters because MLPH is not another anti-DHT drug, and it is not simply another minoxidil-style growth stimulant. It is a designed peptide inspired by the Helix C-1 region of erythropoietin, built to keep a local tissue-growth signal while avoiding the classic blood-building effect that makes full erythropoietin unsuitable as a casual hair-loss treatment.

The headline mechanism is simple enough to understand: MLPH appears to wake up dermal papilla cells through EPOR-linked ERK/AKT signaling, then IGF-1 helps tell the follicle to grow. The caution is just as important: this is still early research. The strongest data so far are from human dermal papilla cells, human hair follicle organ culture, and a mouse anagen model, not a large human hair-loss trial.

The Big Idea: The Dermal Papilla Is the Follicle’s Command Center

Every hair follicle has a tiny signaling hub at its base called the dermal papilla. It is not the hair shaft itself. It is the instruction center that helps decide whether nearby follicle cells proliferate, rest, shrink, survive, or build a thicker shaft.

That is why so many hair-loss mechanisms eventually point back to dermal papilla biology. Androgens can distort dermal papilla signaling in androgenetic alopecia. Wnt signals can help push follicles toward growth. Inflammation can change the follicle microenvironment. Growth factors such as IGF-1, VEGF, KGF and PDGF can help support proliferation, vascularization, and anagen behavior.

The MLPH study is interesting because it does not start with the hair shaft. It starts upstream, at the dermal papilla cell. The researchers designed EPO-derived peptides, tested their ability to bind and signal through the erythropoietin receptor, and then asked whether that signal could make dermal papilla cells behave in a more growth-supportive way.

Step 1: MLPH Borrows the Helpful Part of Erythropoietin Biology

Erythropoietin, or EPO, is best known as a hormone that stimulates red blood cell production. That is useful in medicine, but it is also why EPO cannot be treated like a simple cosmetic hair-growth ingredient. If a compound drives erythropoiesis, it may alter red blood cell count, hemoglobin, hematocrit, clotting risk, and cardiovascular safety.

But EPO biology is broader than blood. Earlier research showed that human hair follicles express EPO and EPO receptor-related machinery, and that EPO can act as a tissue-protective signal outside the bone marrow. Other work reported that EPO receptor expression is present in human dermal papilla cells and that EPO can influence hair shaft growth in culture.

MLPH is built around that opportunity. Instead of using whole EPO, the researchers used Helix C-1-based EPO-derived peptides. The goal was to preserve useful EPOR-linked tissue signaling while removing the overt erythropoietic effect under the tested conditions.

Step 2: EPOR Activation Turns On ERK and AKT

The new paper reports that MLPH and related peptides activated dermal papilla signaling through ERK and AKT. Those are not random lab markers. They are major intracellular pathways involved in proliferation, survival, metabolism, stress resistance, and growth-factor output.

In practical hair terms, ERK/AKT activation in dermal papilla cells may matter because it can help shift the local cell state from passive or stressed toward active and growth-supportive. A follicle does not build a strong shaft because one switch flips. It needs a coordinated environment: proliferating matrix cells, survival signals, growth factors, vascular support, and enough anagen momentum to keep production going.

The study’s mechanism is especially notable because the peptide did not simply produce a vague “cell stimulation” signal. The researchers connected the peptide to EPOR binding, downstream ERK/AKT activity, increased dermal papilla cell metabolic activity and proliferation, reduced oxidative stress, and stronger IGF-1 production.

Step 3: IGF-1 Is the Growth Message That Connects the Signal to the Follicle

IGF-1 is one of the most important growth factors in hair biology. Dermal papilla cells can secrete it, and follicle cells can respond to it through IGF-1 receptor signaling. A 2025 review summarized IGF-1 as a growth factor that supports follicle proliferation, vascularization, anagen transition, anti-apoptotic signaling, and pathways such as PI3K/AKT and MAPK/ERK.

That makes IGF-1 a useful bridge between molecular signaling and visible hair output. If MLPH causes dermal papilla cells to release more IGF-1, the follicle may receive a stronger “keep growing” instruction.

Mechanistically, that could support hair growth in several ways:

• more matrix-cell proliferation, helping the follicle build the hair shaft,
• less apoptosis pressure, helping growth-phase cells survive longer,
• stronger anagen signaling, nudging follicles away from rest and toward active production,
• better growth-factor cross-talk, because IGF-1 can interact with VEGF, KGF, PDGF, Wnt-related signaling and other follicle-supportive pathways,
• improved stress resistance, which matters because oxidative stress can weaken the follicle environment.

This is why the phrase “IGF-1 signaling” should not be dismissed as lab jargon. It is the part of the mechanism that may turn a peptide-receptor interaction into a real follicle growth response.

Step 4: Human Hair Follicle Culture Shows Shaft Elongation

The strongest translational clue in the MLPH paper is the human hair follicle organ-culture result. Dermal papilla cell data are useful, but intact follicle culture is closer to the real target because the follicle keeps epithelial-mesenchymal communication partly intact.

In the study, MLPH-related peptides promoted human hair shaft elongation ex vivo. That means the follicles were outside the body, but still structurally organized enough to test whether the shaft continued growing under treatment.

This is not the same as proving regrowth on a thinning human scalp. Organ culture cannot reproduce the full immune system, androgen environment, vascular supply, skin barrier, sebaceous biology, microbiome, or long-term cycling patterns of a living scalp. But it is much more meaningful than a single-cell assay, because hair shaft elongation is an actual follicle-level output.

Step 5: Mouse Data Suggests Faster Telogen-to-Anagen Entry

The in vivo part of the study used a depilation-synchronized mouse model. In that system, researchers can push follicles into a coordinated resting phase and watch how quickly they re-enter anagen, the active growth phase.

MLPH promoted anagen entry in mice. That fits neatly with the dermal papilla/IGF-1 story: if the dermal papilla sends stronger growth instructions, follicles may move from rest into active production sooner.

But this is also where the caveat gets louder. Mouse hair cycling is not human androgenetic alopecia. A depilated mouse back is not a miniaturizing human frontal scalp. The model is useful for testing anagen biology, but it cannot prove that MLPH will reverse male or female pattern hair loss in people.

Why the “No Blood Side Effects” Claim Needs Careful Reading

The MLPH paper reported no significant changes in standard hematologic parameters under the tested dosing regimen. That included checks designed to look for erythropoiesis-related effects such as red blood cell count, reticulocytes, hemoglobin, and hematocrit.

That is genuinely important because it separates MLPH from the most obvious safety concern around EPO biology. However, it should not be translated into “zero side effects in humans.” It means the peptide did not show overt erythropoietic changes in the tested preclinical setup.

Before anyone can responsibly call this a safe hair-loss treatment, researchers still need:

• pharmacokinetic data, showing how the peptide moves through skin and blood,
• dose-ranging studies, showing how much is enough and how much is too much,
• disease-model testing, especially in androgenetic alopecia-like conditions,
• repeat-dose safety data, because hair treatments are used for months or years,
• human clinical trials, showing real scalp density, shaft caliber, shedding and safety outcomes.

What Is Proven, What Is Plausible, and What Is Still Unknown

What is proven: the 2026 paper reports that MLPH-related EPO-derived peptides engage EPOR-linked signaling in human dermal papilla cells, activate ERK/AKT, increase IGF-1 production, promote dermal papilla cell activity and proliferation, elongate human hair shafts in ex vivo follicle culture, and accelerate anagen entry in a mouse model without significant standard hematology changes under the tested conditions.

What is plausible: MLPH may increase hair growth by making dermal papilla cells secrete more IGF-1, which then supports follicle proliferation, survival, anagen signaling, and shaft production. If that translates to human scalp, it could become a non-hormonal growth-pathway treatment rather than an anti-androgen.

What is still unknown: whether MLPH works in androgenetic alopecia, alopecia areata, telogen effluvium, or other real-world hair-loss conditions; whether topical delivery can reach the right cells; how often it would need to be applied or injected; whether IGF-1 stimulation can be controlled safely; and whether the effect is cosmetically meaningful in humans.

Why This Mechanism Could Pair Well With Existing Treatments

If MLPH eventually works in humans, its mechanism could make it a strong combination candidate. It does not appear to compete directly with the main mechanisms of minoxidil, finasteride, dutasteride, ketoconazole, platelet-rich plasma, low-level light therapy, or microneedling.

In theory:

• anti-androgens reduce miniaturizing DHT pressure,
• minoxidil supports growth output and anagen behavior through non-DHT pathways,
• MLPH may activate dermal papilla EPOR signaling and increase IGF-1,
• microneedling or advanced delivery systems might improve peptide access to follicle-adjacent tissue, though this could also change systemic exposure,
• anti-inflammatory scalp care may improve the background environment so growth signals are not fighting irritation.

The practical takeaway is not that people should try to obtain experimental peptides. They should not. The useful lesson is that future hair-loss treatment may become more modular: one treatment reduces damaging signals, another increases growth signaling, another improves delivery, and another controls inflammation.

How You Can Use This Mechanism Today

MLPH is not a consumer treatment yet, but the mechanism can still help you think more clearly about hair regrowth.

1. Do not treat every peptide claim as equal. The interesting part of MLPH is the EPOR-ERK/AKT-IGF-1 mechanism, not the word “peptide” on its own.
2. Look for follicle-level outcomes. Human hair shaft elongation in organ culture is more useful than a generic cell-growth claim.
3. Separate growth signaling from anti-androgen control. If your hair loss is androgen-driven, a growth signal may help but may not replace DHT management.
4. Be skeptical of “no side effects” headlines. No hematologic changes in a preclinical study is encouraging, but it is not the same as long-term human safety.
5. Watch for real clinical trials. The next important step is human scalp data: hair count, shaft diameter, standardized photos, dose, delivery, adverse events and durability.

The bottom line: MLPH may work by turning dermal papilla cells into stronger IGF-1 broadcasters. It uses an EPO-inspired signal without obvious blood-building effects in the tested model, activates ERK/AKT, increases IGF-1, lengthens human hair shafts outside the body, and pushes mouse follicles toward anagen. That is exciting. But it is still a mechanism, not a proven treatment. The next test is whether this elegant biology can survive the messy reality of human hair loss.

Sources

• MLPH-mediated activation of dermal papilla IGF-1 signaling drives human hair shaft elongation and anagen induction – Kyungpook National University research record
• MLPH-mediated activation of dermal papilla IGF-1 signaling drives human hair shaft elongation and anagen induction – PubMed
• MLPH-mediated activation of dermal papilla IGF-1 signaling drives human hair shaft elongation and anagen induction – ScienceDirect
• Insulin-like Growth Factor 1 (IGF-1) in Hair Regeneration: Mechanistic Pathways and Therapeutic Potential – PubMed
• Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin – PubMed
• Erythropoietin promotes hair shaft growth in cultured human hair follicles and modulates hair growth in mice – PubMed